Introduction
Recent studies have shown that the angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan (Sac/Val), improves outcomes in patients with heart failure with preserved or diminished left ventricular function.1–4 The beneficial effects of Sac/Val have been attributed in part to inhibition of neprilysin, which leads to increases in various peptides, including A-type natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and C-type natriuretic peptide (CNP).5 6 Current guidelines recommend that BNP be measured when making a diagnosis of heart failure, judging its severity or estimating a patient’s prognosis.7 8 However, one study has suggested that BNP should not be used as a marker for heart failure in patients taking Sac/Val because plasma BNP levels will likely be increased due to the drug-induced neprilysin inhibition.9 On the other hand, because BNP is not as good a substrate for neprilysin as ANP or CNP,6 10 the rise in BNP after neprilysin inhibition is actually small.11 Indeed, the results of previous studies indicate that after Sac/Val treatment plasma BNP levels may be increased,12 unchanged5 13 or decreased.14 The reason for the inconsistency in measured BNP levels remains uncertain.
One likely reason for the variation in plasma BNP levels during Sac/Val treatment is patient heterogeneity. A subanalysis of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study showed that patients with a large decreases in NT-proBNP after Sac/Val exhibit modest decreases in BNP and good prognoses, while patients with modest increases in NT-proBNP after Sac/Val treatment exhibit large increases in BNP after Sac/Val and poor prognoses.12 In other words, there may be large differences in BNP responses between responders and non-responders to Sac/Val. In the present study, therefore, we analysed natriuretic peptide (NP) measurements after separating responders and non-responders.
Another reason for the inconsistent results may be the assay system used to measure BNP. BNP immunoassays currently used in clinical settings employ the sandwich method, which entails use of two antibodies, one for capture and the other for detection.15 However, these BNP assay systems currently in use may differently cross-react with the precursor proBNP, considerable amounts of which circulate in human blood.16–18 This may lead to variation in BNP measured with commercial kits (BNPcom) after Sac/Val treatment,19 as mature BNP is subject to degradation by neprilysin, while proBNP is not.20 Moreover, the contribution of proBNP to the overall BNP immunoreactivity varies depending on the patient’s condition, and there are no reports in which plasma levels of proBNP and mature BNP before and after Sac/Val administration were measured.
We previously developed a new chemiluminescence immunoassay for proBNP and total BNP (mature BNP+proBNP) that enables accurate calculation of mature BNP, the proBNP/total BNP ratio and the mature BNP/total BNP ratio in patients with heart failure.21 Using this system, we found that the proBNP/total BNP ratio varies depending on the pathophysiology of the heart failure.22–24 In the present study, we used this method to measure proBNP, total BNP and mature BNP before and after 2, 4, 8 and 12 weeks of Sac/Val administration. In addition, we measured NT-proBNP, ANP and BNPcom using commercially available assays. Our findings shed new light on the mechanism underlying the variation in measured BNP levels after Sac/Val administration.